The Psychedelic News Feed is the audio edition of Psychedelic Alpha's regular news roundup, bringing you a concise update from the worlds of psychedelic drug development, policy, and access.
In it, Psychedelic Alpha Editor Josh Hardman provides a brief review of happenings across the field.
Early Healthcare Forum Takeaways, FDA’s Ibogaine Blueprint, and Compass Talks Pricing
In this episode of The Psychedelic News Feed podcast, Psychedelic Alpha’s editor Josh Hardman runs through the last two weeks in the psychedelics field, including these stories:
Early Notes from The Psychedelic Healthcare Forum
FDA Floats an Ibogaine Trial Design, Asks Field for Input
Compass Talks Pricing, Label and a Slow Launch
New Mexico Nears Medical Psilocybin Launch
Six More Potential Psychedelic Brand Names
Read more:
Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names (https://psychedelicalpha.com/news/p%ce%b1-psychedelic-bulletin-233-fda-floats-ibogaine-trial-design-compass-talks-pricing-potential-lsd-psilocybin-brand-names/)
The Psychedelic Practitioner Issue 7: Preparedness (Systems) (https://psychedelicalpha.com/news/the-psychedelic-practitioner-issue-7-preparedness-systems/)
The Psychedelic News Feed is published by Psychedelic Alpha and airs every two weeks.
This episode of The Psychedelic News Feed is supported by UBC. As psychedelic therapies move toward potential approvals, UBC helps sponsors navigate the evidence generation, pharmacovigilance, and comprehensive risk management strategies that support a path forward grounded in patient safety. Learn more at ubc.com (http://ubc.com).
Send us your questions and comments at pod@psychedelicalpha.com (mailto:pod@psychedelicalpha.com)
Read more and join our newsletter at https://psychedelicalpha.com (https://psychedelicalpha.com)
Follow us on Instagram @psychedelicalpha (https://www.instagram.com/psychedelicalpha), X @Psyched_Alpha (https://x.com/Psyched_Alpha), and LinkedIn (https://uk.linkedin.com/company/psychedelicalpha).
Subscribe to Pα+ for premium insights: https://psychedelicalpha.com/join/ (https://psychedelicalpha.com/join/)
5 Oct 2026
Oregon Backtracks on Fee Hike, California Funds Psychedelic Research, DEA Moves to Schedule 5 Tryptamines
In this episode of The Psychedelic News Feed podcast, Psychedelic Alpha’s editor Josh Hardman runs through another busy two-week period in the field, including:
Oregon Health Authority’s decision to shelve its proposed doubling of fees levied on state-regulated psilocybin entities (ft. Taylor West, Exec. Director, Healing Advocacy)
California carves out $4.7M for psychedelic research
The DEA again moves to schedule 5 tryptamines
The PATH Caucus publishes its RFI white paper
Stanford and UCSF researchers call for “more aggressive” blinding in psychedelic trials (ft. Joshua Woolley, UCSF)
Read more:
Psychedelic Bulletin 232: Oregon Backpedals Psilocybin Fee Hike; DEA Again Moves to Schedule 5 Tryptamines (https://psychedelicalpha.com/news/p%ce%b1-psychedelic-bulletin-232-q226-psychedelic-lobbying-update-dea-again-moves-to-schedule-5-tryptamines-oregon-backpedals-psilocybin-fee-hike/)
The Psychedelic News Feed is published by Psychedelic Alpha and airs every two weeks.
This episode of The Psychedelic News Feed is supported by UBC. As psychedelic therapies move toward potential approvals, UBC helps sponsors navigate the evidence generation, pharmacovigilance, and comprehensive risk management strategies that support a path forward grounded in patient safety. Learn more at ubc.com (http://ubc.com).
Send us your questions and comments at pod@psychedelicalpha.com (mailto:pod@psychedelicalpha.com)
Read more and join our newsletter at https://psychedelicalpha.com (https://psychedelicalpha.com)
Follow us on Instagram @psychedelicalpha (https://www.instagram.com/psychedelicalpha), X @Psyched_Alpha (https://x.com/Psyched_Alpha), and LinkedIn (https://uk.linkedin.com/company/psychedelicalpha).
Subscribe to Pα+ for premium insights: https://psychedelicalpha.com/join/ (https://psychedelicalpha.com/join/)
21 Sept 2026
Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers
In the first episode of The Psychedelic News Feed podcast, Psychedelic Alpha’s editor Josh Hardman runs through a very busy two-week period in the field, including:
Three meetings, or what I’m calling ‘Psychedelics Week’, in D.C.: FDA’s public hearing, an ibogaine-related meeting hosted by ARPA-H, and a congressional briefing
A commentary published by top FDA staff outlining a model for psychedelic drug development
New Zealand’s approval of two psychiatrists to prescribe MDMA
And many other headlines, including: Definium Therapeutics’ Phase 3 LSD for generalised anxiety disorder readout, more data from Compass Pathways’ psilocybin for treatment-resistant depression program, Xylo’s neuroplastogen enters the clinic, Eli Lilly’s acquisition of AtaiBeckley closes, RFK Jr. hosts Bryan Hubbard on his podcast to talk ibogaine, and Usona Institute files a trademark on ‘Arumaya’ a potential brand name for its psilocybin candidate.
Read more:
No Questions Asked: FDA’s Psychedelics Public Hearing (https://psychedelicalpha.com/news/no-questions-asked-fdas-psychedelics-public-hearing/)
‘Move Fast, with Precision’: Notes from ARPA-H’s Ibogaine Workshop (https://psychedelicalpha.com/news/move-fast-with-precision-notes-from-arpa-hs-ibogaine-workshop/)
Psychedelic Bulletin 231 (https://psychedelicalpha.com/news/p%ce%b1-psychedelic-bulletin-231-compass-shares-52-week-follow-up-training-grant-recipients-xylo-enters-the-clinic-rfk-jr-hosts-hubbard/)
Field Notes #5: 'Psychedelics Week' in Washington D.C. (https://psychedelicalpha.com/news/field-notes-5-psychedelics-week-in-washington-d-c/)
Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD (https://psychedelicalpha.com/news/two-new-zealand-psychiatrists-approved-to-prescribe-mdma-for-ptsd/)
Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder (https://psychedelicalpha.com/news/definium-notches-second-positive-phase-3-in-generalised-anxiety-disorder/)
The Psychedelic News Feed is published by Psychedelic Alpha and airs every two weeks.
This episode of The Psychedelic News Feed is supported by UBC. As psychedelic therapies move toward potential approvals, UBC helps sponsors navigate the evidence generation, pharmacovigilance, and comprehensive risk management strategies that support a path forward grounded in patient safety. Learn more at ubc.com (http://ubc.com).
Send us your questions and comments at pod@psychedelicalpha.com (mailto:pod@psychedelicalpha.com)
Read more and join our newsletter at https://psychedelicalpha.com (https://psychedelicalpha.com)
Follow us on Instagram @psychedelicalpha (https://www.instagram.com/psychedelicalpha), X @Psyched_Alpha (https://x.com/Psyched_Alpha), and LinkedIn (https://uk.linkedin.com/company/psychedelicalpha).
Subscribe to Pα+ for premium insights: https://psychedelicalpha.com/join/ (https://psychedelicalpha.com/join/)
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Apple Podcasts (US)
4.9 / 5
13 ratings
Contact The Psychedelic News Feed
Guest appearances
Does not typically book guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
